%0 Journal Article
%A Wurschi, Georg W
%A Hinz, Andreas
%A Schneider, Melanie
%A Becker, Jan-Niklas
%A Frerker, Bernd
%A Vorbach, Samuel M
%A Ehret, Felix
%A Diefenhardt, Markus
%A Schunn, Fabian
%A von Gruben, Maria-Elena
%A Büttner, Marcel
%A Hoffmann, Elgin
%A Rühle, Alexander
%A Beier, Josephine
%A Ferdinandus, Simone
%A Trommer, Maike
%A Sahin, Ezgi Ceren
%A Hlouschek, Julian
%A Aninditha, Kynann
%A von Ohlen, Daphne Schepers
%A Kaufmann, Justus
%A Depardon, Alina
%A Ha, Hai Minh
%A Kessler, Christopher
%A Cieslak, Adrianna
%A Trommer, Simon
%A Fabian, Alexander
%A Rißner, Florian
%A Römer, Maximilian
%A Pietschmann, Klaus
%T Oxaliplatin-induced neuropathy after total neoadjuvant therapy for rectal cancer: Dose-response relationship and impact on quality of life.
%J International journal of cancer
%V nn
%@ 0020-7136
%C Bognor Regis
%I Wiley-Liss
%M DKFZ-2026-00396
%P nn
%D 2026
%Z #DKTKZFB26# / epub
%X Oxaliplatin-based regimens are increasingly used in total neoadjuvant therapy (TNT) for locally advanced rectal cancer, frequently causing dose-limiting chemotherapy-induced peripheral neuropathy (CIPN), whose extent and impact on health-related quality of life (HrQoL) remain insufficiently characterized. The optimal duration and intensity of chemotherapy within TNT for tumor response and toxicity remain unclear. This retrospective multicenter study (DRKS00033000) assessed the dose-response relationship of CIPN with cumulative oxaliplatin dose (cOXAd) and its impact on HrQoL. A total of 227 patients (164 men) with a median age of 63 (Q1-Q3: 54-68) years, who underwent oxaliplatin-based TNT between 2015 and 2024, were analyzed. HrQoL was assessed cross-sectionally during follow-up using the EORTC QLQ-C30 and QLQ-CIPN20 questionnaires. Multivariable logistic regression was applied to evaluate the relationship between cOXAd and CIPN grade ≥2, and known-group comparisons examined differences in HrQoL scores. At follow-up, 61 patients (26.9
%K CIPN (Other)
%K oxaliplatin (Other)
%K polyneuropathy (Other)
%K rectal cancer (Other)
%K total neoadjuvant therapy (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:41704157
%R 10.1002/ijc.70396
%U https://inrepo02.dkfz.de/record/309947